On March 11, 2026, all 16,500 units of the 2nd series stock acquisition rights of Fuji Pharmaceutical Industries Ltd. were exercised, completing fundraising of 3.3 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharmaceutical Industries Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4554-20260311-01.pdf","jir_short_summary":"On March 11, 2026, all 16,500 units of the 2nd series stock acquisition rights of Fuji Pharmaceutical Industries Ltd. were exercised, completing fundraising of 3.3 billion yen.","jir_summary":"### Completion of Exercise of Stock Acquisition Rights\nFuji Pharmaceutical Industries Ltd. announced that all 16,500 units of the 2nd series stock acquisition rights issued on August 5, 2024, with Nomura Securities Co., Ltd. as the allottee, were fully exercised as of March 11, 2026. As a result, fundraising of 3.3 billion yen was realized, and the total number of outstanding shares reached 26,541,100 shares, with capital stock amounting to 5,555,919,505 yen.\n\n### Impact on Shareholders and Future Outlook\nThe exercise of these stock acquisition rights led to the issuance of new shares, which may cause potential dilution of shareholders' equity. For more details, please refer to the \"Notice Regarding Issuance of 1st through 3rd Series Stock Acquisition Rights by Third-Party Allotment\" published on July 18, 2024. There is no information in this document regarding future capital use or business development impact, so these remain unknown.","jir_financial_highlights":"Number of Stock Acquisition Rights Issued: 16,500 units (Unknown)\nNumber of Stock Acquisition Rights Exercised: 16,500 units (Unknown)\nFunds Raised Through Exercise of Stock Acquisition Rights: 3,300,000,000 yen (Unknown)\nTotal Number of Outstanding Shares: 26,541,100 shares (Unknown)\nCapital Stock Amount: 5,555,919,505 yen (Unknown)","jir_category":"","jir_hashtags":"#FujiPharmaceuticalIndustries, #StockOptions, #JapaneseStocks","jir_key_figures":"Number of Stock Acquisition Rights Issued: 16,500 units\nFunds Raised Through Exercise of Stock Acquisition Rights: 3,300,000,000 yen\nTotal Number of Outstanding Shares: 26,541,100 shares","jir_meta_title":"Fuji Pharmaceutical Industries Completes Exercise of 16,500 Units of 2nd Series Stock Acquisition Rights, Raising 3.3 Billion Yen","jir_meta_description":"Fuji Pharmaceutical Industries Ltd. completed full exercise of 16,500 units of its 2nd series stock acquisition rights on March 11, 2026, securing 3.3 billion yen in funding. Total outstanding shares reached 26,541,100 shares.","jir_og_title":"Fuji Pharmaceutical Industries Announces Completion of Exercise of 2nd Series Stock Acquisition Rights","jir_og_description":"On March 11, 2026, all 16,500 units of the 2nd series stock acquisition rights of Fuji Pharmaceutical Industries were exercised, completing fundraising of 3.3 billion yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-34294","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n